Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.

Cato L, Neeb A, Sharp A, Buzón V, Ficarro SB, Yang L, Muhle-Goll C, Kuznik NC, Riisnaes R, Nava Rodrigues D, Armant O, Gourain V, Adelmant G, Ntim EA, Westerling T, Dolling D, Rescigno P, Figueiredo I, Fauser F, Wu J, Rottenberg JT, Shatkina L, Ester C, Luy B, Puchta H, Troppmair J, Jung N, Bräse S, Strähle U, Marto JA, Nienhaus GU, Al-Lazikani B, Salvatella X, de Bono JS, Cato AC, Brown M.

Elife. 2017 Aug 10;6. pii: e27159. doi: 10.7554/eLife.27159.

2.

Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Jehle K, Cato L, Neeb A, Muhle-Goll C, Jung N, Smith EW, Buzon V, Carbó LR, Estébanez-Perpiñá E, Schmitz K, Fruk L, Luy B, Chen Y, Cox MB, Bräse S, Brown M, Cato AC.

J Biol Chem. 2014 Mar 28;289(13):8839-51. doi: 10.1074/jbc.M113.534859. Epub 2014 Feb 12.

3.

The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor.

Shatkina L, Mink S, Rogatsch H, Klocker H, Langer G, Nestl A, Cato AC.

Mol Cell Biol. 2003 Oct;23(20):7189-97.

4.

Bag-1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.

Lee II, Kuznik NC, Rottenberg J, Brown M, Cato ACB.

J Mol Endocrinol. 2019 Mar 1. pii: JME-19-0034.R1. doi: 10.1530/JME-19-0034. [Epub ahead of print] Review.

PMID:
30913537
5.

Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.

Mäki HE, Saramäki OR, Shatkina L, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Cato AC, Visakorpi T.

J Pathol. 2007 Aug;212(4):395-401.

PMID:
17503439
6.

BAG-1L protein enhances androgen receptor function.

Froesch BA, Takayama S, Reed JC.

J Biol Chem. 1998 May 8;273(19):11660-6.

7.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
8.

Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Fujimoto N, Naito S.

Curr Cancer Drug Targets. 2011 Sep;11(7):870-81. Review.

PMID:
21762076
9.

RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV.

Mol Endocrinol. 2012 May;26(5):716-35. doi: 10.1210/me.2011-1130. Epub 2012 Mar 28.

10.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

11.

Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Fujimoto N, Seki N, Naito S.

Mol Endocrinol. 2010 Jan;24(1):114-27. doi: 10.1210/me.2009-0302. Epub 2009 Nov 2.

12.

Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.

Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers N, Cao KH, Haelens A, Claessens F, Revelo MP, Knudsen KE.

Cancer Res. 2008 Jun 15;68(12):4551-8. doi: 10.1158/0008-5472.CAN-07-6392.

13.

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.

Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Epub 2013 Jun 10. Review.

14.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS.

J Biol Chem. 2014 Sep 19;289(38):26417-29. doi: 10.1074/jbc.M114.553818. Epub 2014 Aug 1. Erratum in: J Biol Chem. 2015 Oct 23;290(43):25850. J Biol Chem. 2014 Dec 5;289(49):33877. Hessein, Mohamed [Corrected to Hassona, Mohamed D]. J Biol Chem. 2017 Mar 10;292(10 ):4359.

15.

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.

Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C.

Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.

16.

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.

Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L, Wen JG, Andersen RJ, Sadar MD.

J Biol Chem. 2016 Oct 14;291(42):22231-22243. Epub 2016 Aug 30.

17.

Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.

Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.

J Mol Endocrinol. 2009 May;42(5):429-35. doi: 10.1677/JME-08-0084. Epub 2009 Feb 17.

PMID:
19223455
18.

ARF represses androgen receptor transactivation in prostate cancer.

Lu W, Xie Y, Ma Y, Matusik RJ, Chen Z.

Mol Endocrinol. 2013 Apr;27(4):635-48. doi: 10.1210/me.2012-1294. Epub 2013 Feb 28.

19.

Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

Shiota M, Yokomizo A, Naito S.

J Mol Endocrinol. 2011 Jul 12;47(1):R25-41. doi: 10.1530/JME-11-0018. Print 2011 Aug. Review.

PMID:
21504942
20.

Androgen receptor antagonists for prostate cancer therapy.

Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F.

Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 Mar 17. Review.

PMID:
24639562

Supplemental Content

Support Center